NAYA BIOSCIENCES INC.

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

31 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

24 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

21 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

14 أكتوبر 2024 08:18:20 بحسب Nasdaq GlobeNewswire

INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA

14 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

INVO Reports Record First Quarter 2024 Financial Results

15 مايو 2024 15:15:00 بحسب Nasdaq GlobeNewswire

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

16 أبريل 2024 15:59:29 بحسب Nasdaq GlobeNewswire